Optically active 1-(3-pyridyl)alkanols, chiral self-catalysts, produced themselves of the same configuration in the enantioselective addition of dialkylzinc reagents to pyridine-3-carbaldehyde.
Catalytic asymmetric synthesis of optically active secondary alkynyl alcohols (1 ) by enantioselective addition of organozinc reagents to aldehydes in the presence of a small amount of catalyst was examined. Enantioselective alkynylation of benzaldehyde by alkynylzinc reagents using (1 S,2R) -(-) -N,N-dibutylnorephedrine (2c) as a chiral catalyst gave (1 ) in moderate enantiomeric excess (e.e.). On the other hand, enantioselective addition of dialkylzinc reagents to alkynyl aldehydes using (S) -(+) -(1 -methylpyrrolidin-2-yl)diphenylmethanol (3) as a chiral catalyst afforded (1 ) in high e.e. The reaction of 3-trimethylsilylprop-2-ynal with diethylzinc in toluene at -20 "C using (S) -(+)-(3) (5 mol%) afforded (-) -1 -trimethylsilylpent-1 -yn-3-ol in 78% e.e. (S) -(-)-Oct-1 -yn-3-ol (6) (precursor of the prostaglandin side chain) was also synthesized in 69% e.e. by employing dipentylzinc.
The use of chiral piperazines (cyclic diamines) 1 as chiral catalysts for the enantioselective addition of dialkylzincs t o aldehydes is described. (2S,5S) -2,5-Dialkyl substituted piperazines 1 catalysed the enantioselective addition of dialkylzincs t o aryl aldehydes. It was found that the presence of the dilithium salt of 1 was more effective in producing the corresponding alcohols in high e.e.s (up t o 96% e.e.) and that the catalyst 1 with branched carbon chains as the substituents o n the piperazine ring was effective for highly enantioselective reaction.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.